Published in Annals of Internal Medicine · View the paper (DOI)
A review of 25 trials found that synthetic cannabis products with high THC-to-CBD ratios improved chronic pain, but were associated with higher risks of adverse events. In contrast, products with comparable THC-to-CBD ratios showed few benefits in overall functioning.
Coverage from 2 institutions
- Some cannabis products associated with short-term chronic pain improvements, but side effects a concern American College of Physicians · Jun 6, 2022 · first to report
- Cannabis-related products demonstrate short-term reduction in chronic pain Oregon Health & Science University · Jun 6, 2022